Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 8/20 | 0.62 |
| ▸ | NOS3 | P29474 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710928 | 0.90 | NOS1 (0.64) | NOS1NOS3MEN1KMT2APOLB | |
| SCHEMBL8275649 | 0.89 | NOS1 (0.47) | NOS1NOS3MEN1KMT2APOLB | |
| SCHEMBL8275667 | 0.87 | NOS1 (0.46) | NOS1NOS3MEN1KMT2APOLB | |
| SCHEMBL6710968 | 0.87 | NOS1 (0.48) | NOS1NOS3MEN1KMT2APOLB | |
| SCHEMBL6712176 | 0.87 | NOS1 (0.45) | NOS1NOS3MEN1KMT2APOLB | |
| SCHEMBL8275671 | 0.87 | NOS1 (0.45) | NOS1NOS3MEN1KMT2APOLB | |
| SCHEMBL8459589 | 0.85 | NOS1 (0.43) | NOS1NOS3MEN1KMT2APOLB | |
| SCHEMBL6713301 | 0.84 | NOS1 (0.61) | NOS1NOS3MEN1KMT2APOLB | |
| SCHEMBL5800402 | 0.84 | NOS1 (0.65) | NOS1NOS3MEN1KMT2A | |
| SCHEMBL8275651 | 0.83 | NOS1 (0.42) | NOS1NOS3MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077853-A1 | 2-amino-6-(2,4,5-substituted-phenyl)-pyridines | PFIZER INC. | 2004-04-22 | — | — | US | disclosed |
| US-20040077853-A1 | 2-amino-6-(2,4,5-substituted-phenyl)-pyridines | PFIZER INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2003030993-A1 | 2-AMINO-6-(2,4,5-SUBSTITUTED-PHENYL)-PYRIDINES FOR USE AS NITRIC OXIDE SYNTHASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077853-A1 | 2-amino-6-(2,4,5-substituted-phenyl)-pyridines | NOS3, NOS1, NOS2 | NOS1 2/4885NOS3 1/4885MEN1 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.